Phosphoinositide 3-kinases and leukocyte migration
Reference:
Ward, S. G., 2012. Phosphoinositide 3-kinases and leukocyte migration. Current Immunology Reviews, 8 (2), pp. 154-160.
Related documents:
This repository does not currently have the full-text of this item.You may be able to access a copy if URLs are provided below. (Contact Author)
Official URL:
http://dx.doi.org/10.2174/157339512800099684
Abstract
Phosphoinositide 3-kinase (PI3K) has been positioned at the heart of an evolutionarily conserved cellular compass and/or the biochemical mechanisms that facilitate cell migration. PI3K has therefore, become a popular drug target for inhibition of leukocyte migration in response to inflammatory chemoattractant mediators including members of the chemokine family. PI3K has also been implicated as a key regulator in novel mechanisms mediated by the T cell antigen receptor and the costimulatory molecule CD28 that guide the access and retention of specific T cells into antigenrich non-lymphoid tissue. The precise role of PI3K in the regulation of cell migration remains open to refinement, as numerous examples of PI3K-independent leukocyte migration (particularly with respect to T lymphocytes), have been described. The best studied leukocytes in terms of their migratory response and the role of PI3K are neutrophils and macrophages (that constitute the innate immune response), T lymphocytes (key elements of the adaptive immune response) and eosinophils (typical infiltrating cells at the sites of allergen-IgE reactions that constitute a link between innate and adaptive systems). Genetic and pharmacological approaches have been employed to assess the contribution of individual class 1 PI3K isoforms to migratory response of these leukocytes and will be considered in this article.
Details
| Item Type | Articles |
| Creators | Ward, S. G. |
| DOI | 10.2174/157339512800099684 |
| Departments | Faculty of Science > Pharmacy & Pharmacology |
| Refereed | Yes |
| Status | Published |
| ID Code | 30142 |
Export
Actions (login required)
| View Item |
